166 related articles for article (PubMed ID: 19016350)
1. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer.
Hubert A; Mali B; Hamburger T; Rottenberg Y; Uziely B; Peretz T; Kadouri L
Fam Cancer; 2009; 8(3):173-7. PubMed ID: 19016350
[TBL] [Abstract][Full Text] [Related]
2. Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer.
Drooger JC; Heemskerk-Gerritsen BAM; Smallenbroek N; Epskamp C; Seynaeve CM; Jager A
Breast Cancer Res Treat; 2016 Apr; 156(3):557-566. PubMed ID: 27060914
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
5. Oncotype Dx recurrence score among BRCA1/2 germline mutation carriers with hormone receptors positive breast cancer.
Halpern N; Sonnenblick A; Uziely B; Divinsky L; Goldberg Y; Hamburger T; Peretz T; Kadouri L
Int J Cancer; 2017 May; 140(9):2145-2149. PubMed ID: 28120435
[TBL] [Abstract][Full Text] [Related]
6. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers.
Bignon L; Fricker JP; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Caron O; Lortholary A; Faivre L; Lasset C; Mari V; Gesta P; Gladieff L; Hamimi A; Petit T; Velten M
Breast J; 2018 May; 24(3):269-277. PubMed ID: 28929593
[TBL] [Abstract][Full Text] [Related]
8. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers.
Byrski T; Gronwald J; Huzarski T; Grzybowska E; Budryk M; Stawicka M; Mierzwa T; Szwiec M; Wiśniowski R; Siolek M; Narod SA; Lubinski J;
Breast Cancer Res Treat; 2008 Mar; 108(2):289-96. PubMed ID: 17492376
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
[TBL] [Abstract][Full Text] [Related]
11. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of taxane chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
Kriege M; Jager A; Hooning MJ; Huijskens E; Blom J; van Deurzen CH; Bontenbal M; Collee JM; Menke-Pluijmers MB; Martens JW; Seynaeve C
Cancer; 2012 Feb; 118(4):899-907. PubMed ID: 21761396
[TBL] [Abstract][Full Text] [Related]
13. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
14. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.
Krammer J; Pinker-Domenig K; Robson ME; Gönen M; Bernard-Davila B; Morris EA; Mangino DA; Jochelson MS
Breast Cancer Res Treat; 2017 Jun; 163(3):565-571. PubMed ID: 28343309
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Friedlaender A; Vuilleumier A; Viassolo V; Ayme A; De Talhouet S; Combes JD; Peron J; Bodmer A; Giraud S; Buisson A; Bonadona V; Gauchat-Bouchardy I; Tredan O; Chappuis PO; Labidi-Galy SI
Breast Cancer Res Treat; 2019 Apr; 174(3):775-783. PubMed ID: 30635808
[TBL] [Abstract][Full Text] [Related]
16. Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.
Akdeniz D; van Barele M; Heemskerk-Gerritsen BAM; Steyerberg EW; Hauptmann M; ; van de Beek I; van Engelen K; Wevers MR; Gómez García EB; Ausems MGEM; Berger LPV; van Asperen CJ; Adank MA; Collée MJ; Stommel-Jenner DJ; Jager A; Schmidt MK; Hooning MJ
Breast; 2022 Feb; 61():98-107. PubMed ID: 34929424
[TBL] [Abstract][Full Text] [Related]
17. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
[TBL] [Abstract][Full Text] [Related]
18. Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L; Cimino-Mathews A; Lubeck Y; Daletzakis A; Opdam M; Sanders J; Hooijberg E; van Rossum A; Loncova Z; Rieder D; Trajanoski Z; Vollebergh M; Sobral-Leite M; van de Vijver K; Broeks A; van der Wiel R; van Tinteren H; Linn S; Horlings HM; Kok M
Eur J Cancer; 2020 Mar; 127():240-250. PubMed ID: 31956037
[TBL] [Abstract][Full Text] [Related]
19. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.
van der Kolk DM; de Bock GH; Leegte BK; Schaapveld M; Mourits MJ; de Vries J; van der Hout AH; Oosterwijk JC
Breast Cancer Res Treat; 2010 Dec; 124(3):643-51. PubMed ID: 20204502
[TBL] [Abstract][Full Text] [Related]
20. Clinical and pathological features of BRCA1/2 tumors in a sample of high-risk Moroccan breast cancer patients.
Jouhadi H; Tazzite A; Azeddoug H; Naim A; Nadifi S; Benider A
BMC Res Notes; 2016 Apr; 9():248. PubMed ID: 27129401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
